This week in drug discovery (July 4-8)

A Covid-19 lawsuit, a heart attack treatment developed using spider venom and a collaboration to fight antimicrobial resistance (AMR) are some of the theme’s of this week’s news round-up. 

News round-up by DDW’s Reece Armstrong for 4 – 8 July.

CureVac lawsuit against BioNTech over Covid-19 vaccine technology

Biopharmaceutical company CureVac has filed a lawsuit against BioNTech SE and two of its subsidiaries in relation to an alleged infringement of the company’s portfolio used in the manufacture and sale of the Comirnaty Covid-19 vaccine.

Joint venture launches to fight antimicrobial resistance

A new joint-venture has been formed between Evotec, Boehringer Ingelheim and bioMérieux in a bid to fight antimicrobial resistance (AMR) through the development of new antimicrobials and diagnostics.

Spider venom heart attack treatment closer to clinical trials

A drug candidate for heart attacks which contains venom from a deadly spider has moved closer to clinical trials due to investment of $23 million.

GSK completes acquisition of Sierra Oncology 

GSK has completed its acquisition of the biopharmaceutical company Sierra Oncology, boosting its portfolio of oncology medicines.

Kidney disease has considerable public impact, study says

The burden of chronic kidney disease (CKD) in adult populations has found to be greater than previously estimated, according to the latest real-world evidence study.


Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free